<rt id="ossuk"></rt>
BioXCell熱銷產品--RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A)
產品描述：
10F.9G2™-CP001單克隆抗體是原始10F.9G2™單克隆抗體的重組嵌合型抗體。可變結構域序列與原始10F.9G2™克隆號相同，但是恒定區序列已經從大鼠IgG2b變為小鼠IgG1。10F.9G2™-CP001單克隆抗體在Fc片段中也含有D265A突變，使其無法與內源性Fcγ受體結合。
10F.9G2™-CP001單克隆抗體與小鼠PD-L1（程序性死亡配體1，也稱為B7-H1或CD274）反應。PD-L1是屬于Ig超家族的B7家族的I型跨膜蛋白，分子量為40kDa。PD-L1在T淋巴細胞、B淋巴細胞、NK細胞、樹突狀細胞以及IFNγ刺激的單核細胞、上皮細胞和內皮細胞上表達。PD-L1與CD4和CD8胸腺細胞以及活化的T和B淋巴細胞和骨髓細胞上的受體PD-1結合。PD-L1與PD-1的結合導致抑制TCR介導的T細胞增殖和細胞因子產生。PD-L1被認為在腫瘤免疫逃逸中起著重要作用。誘導的PD-L1表達在許多腫瘤中很常見，并導致腫瘤細胞對CD8+ T細胞介導的裂解的抗性增加。在黑色素瘤的小鼠模型中，可以通過用阻斷PD-L1和PD-1之間相互作用的抗體進行治療，暫時抑制腫瘤生長。10F.9G2™單克隆抗體已被證明可以阻斷PD-L1和PD-1之間以及PD-L1和B7-1之間的相互作用（CD80）。
產品詳情：
產品名稱 | RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A) /欣博盛生物 |
產品貨號 | CP001 |
產品規格 | 1mg |
反應種屬 | Mouse |
克隆號 | 10F.9G2™-CP001 |
同種型 | Mouse IgG1(switched from rat IgG2b) |
免疫原 | Mouse CD274 |
實驗應用 | in vivo PD-L1 blockade* Immunofluorescence* Immunohistochemistry (frozen)* Flow cytometry* Western blot* *Reported for the original rat IgG2b 10F.9G2 antibody |
產品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
純度 | >95%, Determined by SDS-PAGE |
聚合 | <5%, Determined by SEC |
無菌處理 | 0.2 µm filtration |
純化方式 | Protein A |
分子量 | 150 kDa |
小鼠病原檢測 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
保存條件 | 抗體原液保存在4°C，不能冷凍保存。 |
推薦抗體稀釋液 | InVivoPure pH 7.0 Dilution Buffer（貨號IP0070） |
該產品自上市已被多篇SCI文獻引用，品質有保證，以下是部分已發表的文獻引用：
應用 | 文章 |
體內PD-L1阻斷 (in vivo PD-L1 blockade) | 1. Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100. 2. Stathopoulou, C., et al. (2018). 'PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells' Immunity 49(2): 247-263 e247. 3. Jaworska, K., et al. (2015). 'Both PD-1 ligands protect the kidney from ischemia reperfusion injury' J Immunol 194(1): 325-333. 4. Kim, J., et al. (2015). 'Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help' Nat Commun 6: 7994. 5. Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell Host Microbe 17(5): 628-641. |
體內PD-L1阻斷，流式細胞術 (in vivo PD-L1 blockade, Flow Cytometry) | 1. Aloulou, M., et al. (2016). 'Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells' Nat Commun 7: 10579. 2. Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811. 3. Rutigliano, J. A., et al. (2014). 'Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells' J Virol 88(3): 1636-1651. |
體內PD-L1阻斷，免疫熒光 (in vivo PD-L1 blockade, Immunofluorescence) | 1.Willimsky, G., et al. (2013). 'Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance' J Clin Invest 123(3): 1032-1043. |
免疫組織化學（冷凍），免疫熒光 (Immunohistochemistry (frozen), Immunofluorescence) | 1.Riella, L. V., et al. (2011). 'Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts' Am J Transplant 11(4): 832-840. |
更多產品詳情請聯系 BioXCell 中國授權代理——欣博盛生物
在線咨詢
電話咨詢
